Search Results
Your search for ,WHo matches 20837 pages
Showing 251 - 300Acute Cystitis May Signal Urogenital Cancer
Acute cystitis signaled the presence of urogenital cancers in middle-aged men and women, according to the results of a Swedish cohort study published in BMJ Public Health. Based on these findings, the researchers suggested that acute cystitis could be used as a clinical marker for urogenital...
New Approvals for Thrombocytopenia, Lung Cancer, Brain Cancer, and Multiple Myeloma
BTK Inhibitor for Chronic Immune Thrombocytopenia: On September 2, 2025, the U.S. Food and Drug Administration (FDA) approved the Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib (Wayrilz) tablets to treat adults with persistent or chronic immune thrombocytopenia (ITP) who have had an...
Proton Craniospinal Irradiation for Leptomeningeal Metastasis in Lung or Breast Cancer
In an interim analysis of a phase II trial reported in JAMA Oncology, Yang et al found that proton craniospinal irradiation (pCSI) improved central nervous system (CNS) progression-free survival vs photon involved-field radiotherapy (IFRT) in patients who have breast cancer or non–small cell lung...
Oral Microbiota and Risk for Pancreatic Cancer
Investigators have found several oral bacteria and fungi associated with an increased risk for pancreatic cancer, according to findings published in JAMA Oncology. This cohort study seems to confirm a long-standing suspicion of the relationship between poor oral health and pancreatic cancer and...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be well tolerated, including in those with a longer duration of treatment and higher doses. Clinical...
Leading Societies Update Clinical Guideline on Postmastectomy Radiation Therapy
Three leading national cancer organizations have issued an updated guideline on postmastectomy radiation therapy (PMRT) for physicians treating patients with breast cancer. The recommendations outline when PMRT is appropriate based on new evidence and evolving clinical practice, and they highlight...
Policy Review: HRQoL Data in Clinical Trials for Advanced Cancer
A new policy review published by Tannock et al in The Lancet Oncology emphasizes the critical role of health-related quality-of-life (HRQoL) data in the evaluation of treatments for people with advanced cancer. The publication highlights the importance of having standardized responder criteria when ...
Addition of Metastasis-Directed SBRT to Standard Therapy in Oligometastatic Castration-Resistant Prostate Cancer
In a Canadian phase II trial (GROUQ-PCS 9) reported in The Lancet Oncology, Niazi et al found that the addition of metastasis-directed stereotactic body radiotherapy (SBRT) to standard systemic therapy improved radiographic progression-free survival in patients with oligometastatic...
Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO
Chronic myeloid leukemia (CML) is one of the success stories among the hematologic malignancies. Now, with decades of data informing its management, it is time to change some of the practices to which clinicians have become accustomed, said leukemia expert Hagop M. Kantarjian, MD, FASCO, Professor...
Clear-Margin Diagnostic Excisional Biopsy May Adequately Treat Melanoma in Situ, Study Finds
A retrospective cohort study conducted by Dessinioti et al and published in JAMA Dermatology found that, in cases of melanoma in situ, diagnostic excisional biopsy achieving clear margins may be sufficient for treatment. “No local recurrences, metastasis, or melanoma-specific death were observed...
Is TBI Associated With Malignant Brain Tumors?
The results of a retrospective cohort study published in JAMA Network Open revealed an association between having a history of moderate to severe traumatic brain injury (TBI) and the risk of developing malignant brain tumors in adult civilians from the United States. Marini et al confirmed the...
Benmelstobart Plus Anlotinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
In an interim analysis of a Chinese phase III trial (ETER100) reported in The Lancet Oncology, Zhou et al found that the combination of the PD-L1 inhibitor benmelstobart and anlotinib improved progression-free survival vs sunitinib in the first-line treatment of advanced clear cell renal cell...
ASCO Approves First Guideline on Cancer-Specific Geriatric Assessment of Older Patients in Resource-Limited Settings
On April 22, 2025, an ASCO Expert Panel voted to approve ASCO’s global guideline on geriatric assessment of patients with cancer older than age 65 who are being treated in resource-limited settings or countries.1 Guideline recommendations were informed by the ADAPTE methodology and formal consensus ...
JCO Authorship Guidelines Are of Benefit to Those Caring for Older Patients
The aging population, now the largest group of patients with cancer and cancer survivors, requires a rigorous and focused approach to clinical trial reporting, a need highlighted by the recent author guidelines from the Journal of Clinical Oncology (JCO; Table 1).1 The guidelines are an important...
Study Finds High-Risk Prescriptions Drive Frailty, Hospitalization, and Mortality in Older Adults With Cancer
Using the Geriatric Oncology Potentially Inappropriate Medications scale (GO-PIMs), researchers found that older adults are likely to be taking a number of potentially inappropriate or high-risk medications that are associated with increased frailty at the time of their cancer diagnosis, according...
Tislelizumab-Based Triplet Therapy for Conversion of Unresectable to Resectable Locally Advanced Biliary Tract Cancer
In a Chinese phase II trial (ZSAB-TransGOLP) reported in The Lancet Oncology, Shi et al found promising results with tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in converting unresectable locally advanced biliary tract cancer to resectable disease....
Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
In an interim analysis of a phase II trial (SunRISe-4) reported in The Lancet Oncology, Necchi et al found that the addition of neoadjuvant TAR-200—a targeted releasing system that provides sustained delivery of gemcitabine within the bladder—to the PD-1 inhibitor cetrelimab resulted in a higher...
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...
Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies
Many patients from Europe and the United States have experienced the benefits of anthracyclines in the treatment of an array of cancers, including solid tumors such as breast and ovarian cancers as well as lymphoma. However, a number of these cancer survivors will experience severe chronic cardiac...
Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition
Treatment with the viral immunotherapy CAN-2409 helped patients with unresectable, stage III/IV non–small cell lung cancer (NSCLC) continue on immune checkpoint inhibition longer and experience extended survival, despite initial inadequate responses to anti–PD-(L)1 therapy, according to extended...
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from a randomized phase II trial presented at the International...
Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1...
ctDNA May Guide Immunotherapy in Limited-Stage SCLC
A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (Abstract MA11.09) demonstrated that monitoring circulating tumor DNA (ctDNA) may aid in refining and personalizing the use of consolidation immunotherapy in patients with...
Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC
The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC), according to...
Novel Targeted Agent Under Study in MTAP-Deleted NSCLC
BMS-986504, a first-in-class agent targeting MTAP, demonstrated antitumor activity in heavily pretreated patients with MTAP-deleted non–small cell lung cancer (NSCLC), according to findings from the phase I/II CA240-0007 trial presented at the International Association for the Study of Lung Cancer...
Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery
Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...
No OS Benefit for Concurrent and Consolidative Durvalumab vs Consolidation Alone in Unresectable Stage III NSCLC
Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival (OS) compared with consolidation therapy with durvalumab alone, according to research presented...
FDA Approves Kinase Inhibitor for Pediatric Patients With NF1
The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA previously approved selumetinib capsules for...
Overcoming the Challenges of Safely Using Opioids to Treat Patients With Chronic Cancer-Related Pain
Research has shown that pain is among the most commonly experienced and feared aspects of a cancer diagnosis.1 It’s easy to understand why. In fact, cancer-related pain is so ubiquitous, between 20% and 50% of patients with early-stage cancer will experience pain,2 and up to 90% of patients with...
Jeffrey A. Drebin, MD, PhD, Named Chief Physician Executive of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) recently announced that Jeffrey A. Drebin, MD, PhD, has been named Chief Physician Executive. A renowned surgeon-scientist, Dr. Drebin previously served as Chair of the Department of Surgery and brings decades of leadership and clinical experience...
DLL3-Targeted Antibody-Drug Conjugate in Relapsed SCLC
A first-in-human phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, demonstrated manageable safety and early signs of antitumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented at the International...
Previously Treated ES-SCLC: I-DXd Demonstrates High Response Rate
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody-drug conjugate, according to data presented at the International Association for the Study of Lung Cancer...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma
The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...
Do the Results From CARTITUDE-1 Represent a Cure for Patients With Multiple Myeloma? We Need Longer Follow-Up to Know for Sure
The results of the CARTITUDE-1 clinical trial demonstrate outstanding and unprecedented long-term efficacy with ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory multiple myeloma.1 (See the July 2025 issue of The ...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
Experts Share Their Perspectives on Navigating Opioid-Induced Constipation in Oncology
Constipation, a frequent and distressing side effect of cancer treatment, remains underdiagnosed and undertreated—particularly when driven by opioids. Opioid-induced constipation is distinct from functional constipation and requires tailored approaches to assessment and management. During a...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
PARP Inhibition Plus Abiraterone Shows Benefit in HRR-Altered Metastatic Castration-Sensitive Prostate Cancer
Use of the PARP inhibitor niraparib in combination with the androgen biosynthesis inhibitor abiraterone acetate and the corticosteroid prednisone reduced the risk of disease progression, both radiographic and symptomatic, in patients with metastatic castration-sensitive prostate cancer harboring...
Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC
Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...
Novel ADC Shows Promising Efficacy in Previously Treated EGFR-Mutated NSCLC
The first-in-class EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren; BL-B01D1) demonstrated promising efficacy results plus a manageable safety profile in the treatment of patients with previously treated EGFR-mutated non–small cell lung cancer...
Urine-Based Biomarker Panel for the Detection of Prostate Cancer
A novel, urine-based, three-biomarker panel demonstrated significant accuracy and promising sensitivity and specificity for the detection of prostate cancers during development and validation testing, according to findings published in eBioMedicine. “This new biomarker panel offers a promising,...
EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS
A new analysis from the COMPEL trial showed that patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who experienced non–central nervous system (CNS) disease progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based...
GLP-1 RAs and Cancer Risk in Adults With Overweight/Obesity
In a retrospective study reported in JAMA Oncology, Dai et al found that use of GLP-1 receptor agonists (GLP-1 RAs) for weight loss in adults with overweight/obesity was associated with an overall reduction in risk of cancer. As stated by the investigators, “…GLP-1 RAs… are widely prescribed for...
A Year of Global Progress Against Cancer—and Persistent Challenges
Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...
Inherited Variants in 16 Genes May Double the Risk of Multiple Primary Cancers
Individuals carrying a rare pathogenic variant in one of 16 cancer-associated genes were 1.9 times more likely to develop a single cancer and 2.6 times more likely to develop multiple primary cancers, according to the results of a genetic association study published in JAMA Oncology. These...
Can a Common Anti-inflammatory Drug Help to Control Progression of Clonal Hematopoiesis?
Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published by Mohammadnia et al in JACC ...
Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL
Elias Jabbour, MD, discusses long-term findings and predictors of sustained remission among adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who did not undergo a stem cell transplant, but received the chimeric antigen receptor (CAR) T-cell therapy obecabtagene...
Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation
A randomized controlled trial investigating the effect of providing personalized risk information to patients and their providers about the patient’s risk for advanced colorectal neoplasia has found no difference in screening uptake with either the personalized risk messages or provider...
Could a Nasal Spray Help Protect Patients With Cancer Against COVID-19 Infection?
Use of a daily interferon-α nasal spray could significantly reduce the risk of COVID-19 infection among adult patients with cancer, according to the results of a multicenter, randomized trial published in Clinical Infectious Diseases. The results suggest that the nasal spray could be a potential...
